Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity
Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity
In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.
Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity
Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

antibodies
Cancer Vaccines: Raising a T Cell Army
Cancer Vaccines: Raising a T Cell Army
The Scientist Creative Services Team | Apr 1, 2021
Vaccines against various forms of cancer prime the immune system to attack.
Securing the Antibody Supply Chain through Recombinant Antibody Technology: A COVID-19 Case Study
Securing the Antibody Supply Chain through Recombinant Antibody Technology: A COVID-19 Case Study
The Scientist Creative Services Team in collaboration with Sartorius Corporation | Mar 29, 2021
Nicholas Hutchings will discuss how recombinant antibody technology can speed up the response to a pandemic.
COVID-19 Vaccine Combos Aim to Boost Immunity
COVID-19 Vaccine Combos Aim to Boost Immunity
Asher Jones | Mar 9, 2021
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
Understanding Transplant Rejection with Single-Cell Proteomics
Understanding Transplant Rejection with Single-Cell Proteomics
The Scientist Creative Services Team | Mar 9, 2021
Researchers find key drivers of allograft rejection!
Bispecific Antibodies Treat Cancer in Mouse Models
Bispecific Antibodies Treat Cancer in Mouse Models
Abby Olena | Mar 5, 2021
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
NIH Halts Outpatient COVID-19 Convalescent Plasma Trial
NIH Halts Outpatient COVID-19 Convalescent Plasma Trial
Marcus A. Banks | Mar 4, 2021
The decision adds to evidence that the benefits of plasma infusions from COVID-19 survivors may be limited, but advocates say the case isn’t closed.
Q&A: A Molecular Toolkit to Build SARS-CoV-2 Research Capacity
Q&A: A Molecular Toolkit to Build SARS-CoV-2 Research Capacity
Asher Jones | Mar 3, 2021
Sam Wilson discusses a user-friendly set of resources that he and his collaborators developed to aid labs pivoting to study COVID-19.
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Marcus A. Banks | Mar 1, 2021
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Technique Talk: Improving IHC and IF Staining Results
Technique Talk: Improving IHC and IF Staining Results
The Scientist Creative Services Team in collaboration with Vector Laboratories | Feb 18, 2021
In this workshop, Craig Pow will explore optimizing IHC and IF staining workflows.